• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, January 11, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Examining therapeutic targets for kidney disease

Bioengineer by Bioengineer
January 13, 2021
in Chemistry
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

University of Houston researcher tackles proteins found in disease

IMAGE

Credit: University of Houston

Among the primary forms of kidney disease, focal segmental glomerulosclerosis (FSGS) is the most common and is marked by high circulating levels of the suPAR protein (soluble urokinase-type plasminogen activator receptor). In the past year, high serum suPAR levels have also been found to predict kidney and multiple organ failure in hospitalized patients with COVID-19.

“FSGS is a particularly insidious kidney disease. In many patients, it inexorably leads to kidney failure and we don’t have much to offer to stop it, and worse still, in many patients it recurs after a kidney transplant, leading to failure of the transplanted kidney,” said Stuart E. Dryer, Moores Professor of biology and biochemistry, who has a joint appointment as a professor of biomedical sciences in the UH College of Medicine. Dryer is working to identify potential new therapeutic targets for chronic kidney disease, especially focal segmental glomerulosclerosis, and his first place to look is the suPAR protein.

Increased suPAR levels in blood induce oxidative stress in the glomeruli, the tiny filtering units within the kidney, and release oxygen-free radicals that attack cell membranes and disrupt ion channels, causing a rise in calcium levels inside the cell. In many conditions, high suPAR levels have bad prognostic indications.

“Basically, if you are sick and your serum suPAR levels are high, you’re in trouble,” said Dryer. To block the actions of suPAR, he is examining a drug that has already undergone clinical trials for unrelated conditions, including Alzheimer’s disease. A $1.4 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases supports his work.

“It started as a very lucky guess actually, but we’ve shown it in a dish, that we can take isolated cells and if we treat them with suPAR they develop oxidative stress and if we add this drug, that doesn’t happen,” said Dryer.

Dryer’s other favorite target is an ion channel protein called TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6). Excessive activation of TRIPC6 causes FSGS and suPAR greatlyg increases the activity of TRPC6.

“My lab has shown the suPAR and TRPC6 are connected to one another,” said Dryer. “If you add suPAR to cells, TRPC6 becomes more active,” said Dryer. “Now we need to understand better how TRPC6 actually works in relevant kidney cells.”

###

Media Contact
Laurie Fickman
[email protected]

Original Source

https://uh.edu/news-events/stories/2021/january-2021/01132021-stuart-dryer-kidney-targets-supar-grant.php

Tags: BiochemistryBiologyBiotechnologyCell BiologyClinical TrialsDiabetesInternal MedicineMedicine/HealthMetabolism/Metabolic Diseases
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Advancing Alkene Chemistry: Homologative Difunctionalization Breakthrough

January 8, 2026
Biocompatible Ligand Enables Safe In-Cell Protein Arylation

Biocompatible Ligand Enables Safe In-Cell Protein Arylation

January 8, 2026

Monovalent Pseudo-Natural Products Boost IDO1 Degradation

January 7, 2026

Catalytic Enantioselective [1,2]-Wittig Rearrangement Breakthrough

January 7, 2026
Please login to join discussion

POPULAR NEWS

  • Enhancing Spiritual Care Education in Nursing Programs

    154 shares
    Share 62 Tweet 39
  • PTSD, Depression, Anxiety in Childhood Cancer Survivors, Parents

    146 shares
    Share 58 Tweet 37
  • Robotic Ureteral Reconstruction: A Novel Approach

    65 shares
    Share 26 Tweet 16
  • Impact of Vegan Diet and Resistance Exercise on Muscle Volume

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tailored MobileNetV3Large Framework for Detecting Plant Diseases

How Organizational Support Influences Nurses’ Leadership in Tunisia

Linking Lifestyle Choices to Teen Mental Health Worldwide

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 71 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.